Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year’s end, tapping Harbour ...

As the FDA steadily churns out a stream of untitled letters chastising pharmaceutical advertisers’ direct-to-consumer ...

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb ...

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.

Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement ...

After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a ...

Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. Agenus ...

After several years of turning out solid growth, Bristol Myers Squibb knows it’s nearing a patent cliff that’ll wreak havoc later this decade. Still, the company believes a “diversified” ...

Biopharmaceutical firm Bristol Myers Squibb (BMS) and IT services company Accenture on Wednesday announced the opening of a ...

On April 25, I wrote about an appeal Jason Hughes made on Twitter. The Tesla Hacker urged people not to reset their Model S units with BMS_u029 or BMS_u018 error ...

BMS Group has announced a strategic partnership with Berns Brett India, signalling its expansion into the Indian market, with ...